AT₁ blockers – comparability with ACE inhibitors

Česká verzia

Authors: Václav Monhart ^1,2
Authors place of work: Interní klinika 1. LF UK a ÚVN – VFN Praha ¹; Ambulance nefrologie, Synlab Czech s. r. o., Praha ²
Published in the journal: Vnitř Lék 2017; 63(4): 267-271
Category: Přehledné referáty

Summary

The reduction in overall mortality, cardiovascular mortality and the occurrence of myocardial infarction in patients treated with AT₁ blockers is comparable with the use of ACE inhibitors. In addition, there is a lower proportion of AT₁ blockers withdrawal of treatment due to adverse reactions.

Key words:
ACE inhibitors –⁠ AT₁ blockers –⁠ cardioprotection –⁠ hypertension –⁠ renin-angiotensin-aldosteron system

Zdroje

1. Mielke MM, Rosenberg PB, Tschanz J et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology 2007; 69(19): 1850–1858.

2. Roselli F, Tartaglione B, Federico F et al. Rate of MMSE score change in Alzheimer’s disease: influence of education and vascular risk factors. Clin Neurol Neurosurg 2009; 111(4): 327–330. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clineuro.2008.10.006>.

3. Poulter N. ARBs in hypertension. Br J Cardiol 2010; 17(Suppl): s6-s9. Dostupné z WWW: <https://bjcardio.co.uk/2010/05/arbs-in-hypertension/>.

4. Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev 2014; (8): CD009096. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD009096.pub2>.

5. Abraham HM, White CM, White WB. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Saf 2015; 38(1): 33–54. Dostupné z DOI: <http://dx.doi.org/10.1007/s40264–014–0239–7>.

6. Dézsi CA. The different therapeutic choices with ARBs. Which one to give? When? Why? Am J Cardiovasc Drugs 2016; 16(4): 255–266. Dostupné z DOI: <http://dx.doi.org/10.1007/s40256–016–0165–4>.

7. Verdecchia P, Angeli F, Cavallini C et al. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J 2009; 30(6): 679–688. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehn575>.

8. Verdecchia P, Gentile G, Angeli F et al. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers. Ther Adv Cardiovasc Dis 2012; 6(2): 81–91. Dostupné z DOI: <http://dx.doi.org/10.1177/1753944712444866>.

9. Bangalore S, Fakheri R, Toklu B et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials. Mayo Clin Proc 2016; 91(1): 51–60. Dostupné z DOI: <http://dx.doi.org/10.1016/j.mayocp.2015.10.019>.

10. Widimský J, Widimský J, jr. Esenciální a sekundární hypertenze pro praxi. Triton: Praha 2005. ISBN 80–7254–711–9.

11. Widimský J, Monhart V. Antagonisté receptorů angiotenzinu II. typu AT1 (AT1 blokátory). In: Widimský J et al. Hypertenze. 3. vyd. Triton: Praha 2008 : 362–379. ISBN 978–80–7387–077–5.

12. Widimský J, Monhart V. Antagonisté receptorů angiotenzinu II. typu AT1 (AT1 blokátory). In: Widimský J et al. Antagonisté renin-angiotenzin-aldesteronového systému. Triton: Praha 2011 : 113–158. ISBN 978–80–7387–499–5.

13. Widimský J, Widimský J jr. Farmakoterapie hypertenze. Maxdorf: Praha 2016. ISBN 978–80–7345–477–7.

14. Van Zwieten PA, Farsang C. Interactions between antihypertensive agents and other drugs. Blood Press 2003;12(5–6):351–352.